MTHFR - (Methyl Tetra Hydro Folate Reductase) Gene Mutation (Homocysteinemia)

The MTHFR gene mutation can reduce activity of the MTHFR enzyme, impairing folate metabolism and methylation. This may raise homocysteine levels and modestly increase risks like neural tube defects in pregnancy and certain vascular or clotting problems. Common variants (C677T, A1298C) vary in effect; many carriers are asymptomatic and clinical impact depends on genotype, diet (folate/B12), and other health factors.

If you have an MTHFR variant, discuss results with your doctor or a genetic counselor to assess clinical relevance. Check folate, vitamin B12 and homocysteine levels. If needed, your clinician may recommend dietary folate and B‑vitamin supplementation (often L‑methylfolate rather than folic acid) and monitor response. During pregnancy or when planning conception, seek specialist guidance. Avoid self-prescribing high‑dose supplements.

Avoid foods high in synthetic folic acid: fortified cereals, enriched breads, pasta and flour products, fortified snack bars and vitamin‑fortified drinks, and heavily processed foods with added folic acid. Also limit alcohol, which impairs folate use. Prefer natural folate from leafy greens, legumes and citrus, and discuss methylfolate supplementation with your healthcare provider.

Variants in the MTHFR gene (notably C677T and A1298C) have been linked to higher homocysteine and an increased risk of depression, bipolar disorder, schizophrenia, and anxiety. Associations are modest and not strictly causal, but variants can affect folate metabolism and treatment response; adjunctive methylfolate supplementation or tailored antidepressant strategies are sometimes recommended by clinicians.

MTHFR gene variants can impair folate metabolism and may cause neurological symptoms such as numbness, tingling or peripheral neuropathy; headaches and migraines; cognitive issues (memory loss, brain fog, slowed processing); mood disorders like depression and anxiety; balance or coordination problems; developmental delays in children; seizures and an increased stroke risk in severe cases. Severity varies and many carriers have no symptoms.

Doctors are skeptical because common MTHFR gene variants are frequent and usually don't cause disease. Evidence linking them to many health problems is weak or inconsistent, and major clinical guidelines don't recommend routine testing. Testing can prompt unnecessary or unproven treatments. Clinicians prefer to assess and treat clear folate or B12 deficiencies and clinical signs rather than rely on MTHFR results alone.